Sanofi (FRA:SNW)
Germany · Delayed Price · Currency is EUR | Market Cap | 88.91B -9.5% |
| Revenue (ttm) | 48.92B +7.0% |
| Net Income | 3.96B -56.6% |
| EPS | 3.26 -55.6% |
| Shares Out | n/a |
| PE Ratio | 22.46 |
| Forward PE | 8.41 |
| Dividend | 4.12 (5.57%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 1,157 |
| Open | 74.40 |
| Previous Close | 73.40 |
| Day's Range | 74.35 - 75.31 |
| 52-Week Range | 71.72 - 90.46 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Sanofi Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Management is focused on sustaining specialty care growth, expanding core areas, and balancing early- and late-stage deal-making to address future revenue needs. Dupixent's growth is driven by low biopenetration and lifecycle management, while operational and R&D rigor underpin pipeline execution.
Sanofi, Cheplapharm enter strategic partnership
Sanofi (SNY) and Cheplapharm announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing ...
Sanofi To Receive 26.4% Stake In Cheplapharm For Mature Medicines
(RTTNews) - Sanofi (SNY, SAN.PA), a healthcare company, on Monday announced an agreement with Cheplapharm to create a strategic partnership for its mature medicines portfolio.
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Sanofi and Cheplaphar m to create new strategic partnership i n mature medicines
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-ter...
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Analysts Think These Stocks Could More Than Double in ValueNovavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model...
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™
MORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026 /PRNewswire/ -- Sanofi and USA Pickleball are teaming up to launch "Serve Up Protection," a campaign to educate older adults about COVID-19 and N...
Sanofi price target raised to EUR 100 from EUR 95 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on Sanofi (SNY) to EUR 100 from EUR 95 and keeps a Buy rating on the shares. The firm adjusted targets…
Sanofi initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Sanofi (SNY) with a Sector Perform rating and EUR 80 price target Near-term challenges include limited catalysts, Dupixent’s patent cliff, and skepticism about delive...
Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
Emmy Award-winning actress, entrepreneur and mom Keke Palmer partners with Sanofi to help educate families about protection against a serious respiratory syncytial virus (RSV) lung infection BEYFORTUS...
Novavax's XFG-Adapted Nuvaxovid Approved In U.S., EU, Japan For 2026-2027 Season
(RTTNews) - Novavax, Inc. (NVAX) on Friday announced that its partners, Sanofi and Takeda, have received regulatory approvals for XFG-adapted Nuvaxovid COVID-19 vaccine for the 2026-2027 vaccination s...
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?
The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside potential ahead for shares of the French pharmaceutical giant.
Sanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley
Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Sanofi (SNY) to EUR 82 from EUR 86 and keeps an Equal Weight rating on the shares. Published first…
Sanofi facing shortages of two drugs for Pompe disease, STAT reports
Sanofi (SNY) is facing shortages of Myozyme and Nexviazyme for Pompe disease after manufacturing and quality-control issues at its Waterford facility, which was cited by the FDA in June for…
Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has a...
Sanofi Q2 Earnings Call Highlights
Sanofi NASDAQ: SNY raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also ...
Sanofi Earnings Call Transcript: Q2 2026
Q2 2026 saw double-digit sales and EPS growth, driven by strong pharma launches and Dupixent. Upgraded 2026 guidance reflects robust H1 results, with raised 2030 ambitions for Dupixent, pharma launches, and vaccines. Strategic R&D and portfolio reviews are underway to enhance long-term growth.
Sanofi Earnings release: Q2 2026
Sanofi released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Sanofi Slides: Q2 2026
Sanofi has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Sanofi Earnings release: Q2 2026
Sanofi released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Sanofi Quarterly report: Q2 2026
Sanofi has published its Q2 2026 quarterly earnings report on July 30, 2026.
Sanofi expects FY26 sales to grow by around 10% at CER
In 2026, sales are now expected to grow by around 10% at CER. Business EPS at CER is expected to grow slightly faster than sales.
Sanofi reports Q2 business EPS EUR 2.09, up 31.4% reported
Business EPS was EUR 2.09, up by 33.3% at CER; 31.4% at actual exchange rates; IFRS EPS EUR 0.29. Reports net sales EUR 11.6B, up 16% reported and 17.8% at…
Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline
The company now expects 2026 sales to grow by around 10% excluding currency changes, with business earnings per share rising slightly faster than sales.